Completed PHASE1 INTERVENTIONAL 2-arm NCT05357820

A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK

A Phase I, Single-center, Open-label, Fixed-sequence Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 Pharmacokinetics

Sponsor: Nuvation Bio Inc.

Conditions Solid Tumor

Interventions AB-106, Itraconazole AB-106, Rifampicin

Updated 4 times since 2022 Last updated: Nov 19, 2024 Started: Jul 19, 2021 Primary completion: Dec 3, 2021 Completion: Dec 3, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Solid Tumor and is currently completed. Nuvation Bio Inc. leads this study, which shows 4 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Dec 2024 — Present [monthly]

Completed PHASE1
Sep 2024 — Dec 2024 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jun 2022 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nuvation Bio Inc.

Data source: Nuvation Bio Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China